
Please try another search
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company’s products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Karen Cichowski | - | - | Scientific Advisory Board Member |
Pablo Rodriguez-Viciana | - | - | Scientific Advisory Board Member |
Kevan M. Shokat | - | - | Scientific Advisory Board Member |
Jonathan E. Lim | 52 | 2018 | Co-Founder, Chairman & CEO |
Ryan B. Corcoran | - | - | Scientific Advisory Board Member |
George Daniel Demetri | 67 | - | Scientific Advisory Board Member |
Stephen C. Blacklow | - | - | Scientific Advisory Board Member |
Bruce D. Roth | - | - | Member of Research, Development, & Commercial Advisory Board |
James A. Bristol | 78 | 2018 | Lead Independent Director |
Julie Hambleton | 67 | 2021 | Independent Director |
Valerie Harding-Start | 65 | 2019 | Independent Director |
Pratik S. Multani | 58 | 2018 | Independent Director |
Alexander Whitman Casdin | 57 | 2018 | Independent Director |
Michael D. Varney | 67 | 2020 | Chairman of Research & Development, Scientific Advisory Board Member and Director |
John Lo | - | 2022 | Senior Commercial Advisor & Member of Research, Development and Commercial Advisory Board |
Jean I. Liu | 57 | 2022 | Independent Director |
Gregory Cosma | - | - | Member of Research, Development, & Commercial Advisory Board |
Piro Lito | - | 2025 | Member of Scientific Advisory Board |
Jean-Michel Vernier | 63 | 2025 | Senior Chemistry Advisor & Member of Research, Development and Commercial Advisory Board |
Rene Bernards | 72 | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review